Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 674 of 5804
-
Hope for advanced breast cancer: new combo targets resistant tumors
Disease control OngoingThis study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take on liver cancer in new trial
Disease control Recruiting nowThis is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, …
Phase: PHASE1, PHASE2 • Sponsor: Eureka Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Dissolving stent could revolutionize heart disease treatment
Disease control OngoingA prospective, multi-center, single-arm trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease.
Phase: NA • Sponsor: Biotyx Medical (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for lymphoma patients: zanubrutinib combo enters phase 3 trial
Disease control OngoingThe purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Cooling probe may shield esophagus during heart ablation for AF
Disease control CompletedAtrial fibrillation (AF) is a common debilitating heart rhythm condition that can cause heart failure and negatively impact a patient's outlook in terms of symptoms and disability. It is an irregular fast heart rhythm disorder coming from the top chamber of the heart (left atrium…
Phase: NA • Sponsor: Advanced Cooling Therapy LLC, d/b/a Attune Medical • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Gene therapy for rare immune disease shows promise in Long-Term study
Disease control OngoingThis Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the …
Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug shows promise for tough lung cancer
Disease control OngoingThis 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of …
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug aims to block sickle cell pain crises
Prevention CompletedThis study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Prevention
Last updated Jun 27, 2026 12:26 UTC
-
Triple threat: new combo aims to tackle breast cancer brain metastases
Disease control OngoingThis study is a Phase I/II study evaluating the safety and effectiveness of focused radiation therapy (radiosurgery) together with olaparib, followed by immunotherapy, for patients with brain metastases from triple negative or BRCA-mutated breast cancers. This study will have a …
Phase: PHASE1, PHASE2 • Sponsor: Colette Shen • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could a Heart-Healthy diet tame uncontrolled asthma?
Disease control CompletedThe goal of the ALOHA trial is to investigate the efficacy of improved diet quality following a DASH behavioral intervention that has shown promising results in adults with uncontrolled asthma. DASH stands for Dietary Approaches to Stop Hypertension. This healthy diet is known to…
Phase: PHASE2, PHASE3 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could an allergy pill and diabetes drug fix MS nerve damage?
Disease control CompletedThe greatest unmet need for people with multiple sclerosis is an effective therapy for the progressive phase. Current treatments suppress the damage caused by the immune system but there is only a limited window in which these can work. Consequently, much of the research communit…
Phase: PHASE2 • Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a few shots replace weeks of IV antibiotics for joint infections?
Disease control OngoingOsteoarticular infections associated with hip and knee prostheses require optimal surgical and medical management to maximize the rate of therapeutic success. Antibiotic therapy should be administered for a period of 12 weeks. Tolerance problems, difficulties in maintaining compl…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Implantable nerve stimulator shows promise for bladder control
Disease control OngoingProspective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Phase: NA • Sponsor: Coloplast A/S • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for advanced endometrial cancer: immunotherapy combo under study
Disease control Recruiting nowThis is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo aims to control Hard-to-Treat leukemia
Disease control OngoingThis phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3 attaches to IL3 receptor posi…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug duo aims to slow advanced lung cancer
Disease control OngoingThis study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New cocktail aims to boost chemo power against aggressive lymphoma
Disease control OngoingThis phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab alone and in combination with chemotherapy in treating patients with newly diagnosed non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasitamab are monoclonal antibodie…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
CAR-T therapy shows promise for Hard-to-Treat myeloma, but trial ends early
Disease control TerminatedThis is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New dosing strategy aims to tame eye side effects in myeloma drug
Disease control CompletedThis study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, sc…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to shrink breast tumors before surgery, spare chemo
Disease control OngoingPatients with estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) breast cancer do not achieve good responses with pre-operative chemotherapy. The sensitivity of breast cancer to chemotherapy is often determined by the underlying gene expression pattern a…
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC